Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Monte Rosa Therapeutics (GLUE) EBT Margin (2024 - 2025)

Historic EBT Margin for Monte Rosa Therapeutics (GLUE) over the last 2 years, with Q3 2025 value amounting to 236.98%.

  • Monte Rosa Therapeutics' EBT Margin rose 211300.0% to 236.98% in Q3 2025 from the same period last year, while for Sep 2025 it was 12.09%, marking a year-over-year increase of 8067800.0%. This contributed to the annual value of 92.74% for FY2024, which is N/A changed from last year.
  • According to the latest figures from Q3 2025, Monte Rosa Therapeutics' EBT Margin is 236.98%, which was up 211300.0% from 47.84% recorded in Q2 2025.
  • In the past 5 years, Monte Rosa Therapeutics' EBT Margin ranged from a high of 56.17% in Q1 2025 and a low of 2996.71% during Q1 2024